The Food and Drug Administration may be in one of its bipolar moods, but fortunately for Johnson & Johnson
After giving the company a complete response letter in February, the agency approved Risperdal Consta for the treatment of bipolar disorder. Apparently whatever was holding up the approval wasn't a major obstacle.
The drug, a long-lasting version of Risperdal designed with technology from Alkermes
Bipolar disorder isn't as severe as schizophrenia, so the main selling point of Risperdal Consta -- biweekly administration -- won't be as big a selling point over Risperdal, which recently went generic. But there are a certain subset of patients having trouble staying on daily meds like Risperdal, AstraZeneca's
After Vanda Pharmaceuticals'
In hot and cold markets, we've got you covered:
Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.